LUM001 (Maralixibat) ( DrugBank: Maralixibat )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
297	Alagille syndrome	2

297. Alagille syndrome

---

Clinical trials : 43 /  Drugs : 19 - (DrugBank : 9) / Drug target genes : 2 - Drug target pathways : 2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02117713 (ClinicalTrials.gov)	March 16, 2015	16/4/2014	An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome	A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome	Alagille Syndrome	Drug: LUM001 (Maralixibat)	Mirum Pharmaceuticals, Inc.	Lumena Pharmaceuticals, Inc.;Childhood Liver Disease Research and Education Network	Completed	1 Year	18 Years	All	34	Phase 2	United States;Canada
2	NCT02047318 (ClinicalTrials.gov)	December 20, 2013	23/1/2014	An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)	A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001 Also Known as Maralixibat (MRX), an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome	Alagille Syndrome	Drug: LUM001 (Maralixibat)	Mirum Pharmaceuticals, Inc.	NULL	Completed	12 Months	18 Years	All	19	Phase 2	United Kingdom